RenovoRx, Inc.

As of June 20, 2025, the technical trend is bullish with strong indicators like the weekly MACD and Bollinger Bands supporting this outlook, although a bearish KST signal and mildly bearish Dow Theory on the weekly slightly temper the overall sentiment.

RenovoRx, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $2 million as of March 2025, with a market cap of $49.37 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -84.75%.

As of Jun 18, RenovoRx, Inc. has a market capitalization of 49.37 million, with net sales of 0.24 million and a net profit of -10.16 million over the latest four quarters. The company reported shareholder's funds of 4.48 million and total assets of 8.20 million as of Dec 24.